A more tractable strategy is to modulate pathways regulated by FOXD1, and in this study we used a transcriptomic analysis to identify specific pathways downstream from FOXD1 that can be pharmacologically modulated to suppress the G2/M transition in ccRCC tumor cells. The gene discussed is FOXD1; the disease is neoplasm.